
IsomAb appoints CEO to lead development of angina treatment
Biotechnology company IsomAb has appointed Dr Philip Brainin as Chief Executive Officer as it looks to enter clinic with a treatment for chronic stable angina (CSA). Brainin arrives with experience in cardiovascular medicine, clinical research, and venture investing across EU and US biotechnology companies. He has previously invested in… Read More


